Elevation Oncology, Inc. - ELEV Operating profit EBITDA
The precision oncology market remains open, encouraging Elevation Oncology (ELEV) to expand partnerships with pharmaceutical behemoths. The operational benefit trend illustrates the current cash flow, where determines the current value of the metric. The company's prospects rely on the development of targeted drugs through grants, although risks of high capital burn and dependence on the success of clinical trials persist.
Summary analytical data breakdowns for Elevation Oncology (ELEV)
- current quotes and average value forecast:
- issuer market value details:
- book value of equity indicators:
- debt level and financial liquidity data:
- earnings and market ratios statistics:
ELEV - Net Income|Future Net Profit Elevation Oncology|ELEV - P/E Multiple|Market Cap to Projected Earnings Elevation Oncology Inc.|ELEV - Price/Earnings to Growth Ratio|Company Value to EBITDA Elevation Oncology|ELEV - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Elevation Oncology|ELEV - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months elevationoncology.com|ELEV - Earnings per share growth in current year|Expected net earnings per share growth next year Elevation Oncology
Summary company analytics:Elevation Oncology
This indicator tracks daily net operating income, allowing for the monitoring of cash flow dynamics and the timely identification of critical resource depletion for business development. An analysis of Elevation Oncology (ELEV) consolidated EBITDA highlights the risks associated with early-stage drug development, where the absence of revenue and research expenditures make this chart a key signal for the capital burn rate.
Competitor analysis for Elevation Oncology
ONC - Operating profit before deduction of amortization|HALO: Operating profit before deduction of amortization|RVMD - Operating profit EBITDA|Ascentage Pharma (AAPG) - Profit before payment of interest, taxes and amortization|CG Oncology Inc - Income before deduction of interest, taxes and amortization|URGN (UroGen) - Operating profit EBITDA|Profit before interest, taxes and amortization Bicara Corp BCAX|Operating profit EBITDA PSNL|ERAS - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization Delcath Systems DCTH|Y-mAbs Therapeutics Inc - Profit before payment of interest, taxes and amortization|Aura Bio - Operating profit EBITDA|Profit before interest, taxes and amortization Candel Therapeutics|ARAY (Accuray Incorporated) - Operating profit before deduction of amortization|SLS (SELLAS Life Sciences Group) - Profit before payment of interest, taxes and amortization|ACTU (Actuate Therapeutics) - Operating profit EBITDA|Operating profit EBITDA Citius Oncology Inc.|Operating profit before deduction of amortization HURA (TuHURA Biosciences, Inc.)|Company profit before taxes, interest and amortization TARA|Operating profit EBITDA FATE (Fate Therapeutics, Inc.)|Operating income before deduction of amortization Aadi Bioscience, Inc. (WHWK)|TCRX - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Champions Oncology|xbiotech.com (XBIT) - Profit before payment of interest, taxes and amortization|Operating profit before amortization CVM|Operating profit before deduction of amortization OSTX|RADX: Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Artiva Biotherapeutics, Inc. (ARTV)|ANL - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization Veru Pharma VERU|TPST: Operating profit before amortization|Xilio - Operating profit EBITDA|Renovaro Inc. (RENB) - Operating profit before deduction of amortization|muraloncology.com (MURA) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Kairos Pharma (KAPA)|Profit before payment of interest, taxes and amortization OnKure Therapeutics, Inc.|Profit before payment of interest, taxes and amortization GDTC|Profit before payment of interest, taxes and amortization Curis, Inc. (CRIS)|APLM - Profit before interest, taxes and amortization|Operating profit EBITDA THAR (Tharimmune)|Operating profit before depreciation charges Advanced Biomed Inc.|GNPX: Operating profit before deduction of amortization|Profit before interest, taxes and amortization Calidi Biotherapeutics|SBFM: Operating profit EBITDA|Profit before interest, taxes and amortization Xenetic Biosciences, Inc. (XBIO)|Profit before payment of interest, taxes and amortization Salarius Pharmaceuticals, Inc.|Profit before payment of interest, taxes and amortization PPBT|Operating profit EBITDA AONC|BGNE - Profit before interest, taxes and amortization|Checkpoint Therapeutics - Operating profit before deduction of amortization|iCAD Inc. - Profit before payment of interest, taxes and amortization|Ikena - Operating profit EBITDA|Notable Labs Ltd (NTBL) - Operating profit before deduction of amortization|VIRX: Operating profit EBITDA|MorphoSys Corporation (MOR) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization NAYA Biosciences|Operating profit before amortization AAPGV (ascentage.com)
